TMPRSS2 and Dravet syndrome: In our clinical report, complementing the perspective described by [14], we must question if under the same argument of the triple dose effect, the overexpression of TMPRSS2 (also located at 21q22.3) at the pulmonary level could be related to a possible increase in the susceptibility for severe COVID-19 disease in patients with DS.